Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1995 1
1996 2
1998 3
1999 2
2000 1
2001 6
2002 5
2003 4
2004 4
2005 9
2006 9
2007 7
2008 18
2009 13
2010 22
2011 16
2012 12
2013 25
2014 20
2015 19
2016 20
2017 17
2018 20
2019 14
2020 9
2021 15
2022 9
2023 14
2024 7
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Ponsioen CY, et al. Among authors: van bodegraven aa. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Lancet Gastroenterol Hepatol. 2017. PMID: 28838644 Clinical Trial.
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE; GALAXI 2 & 3 Study Group. Panaccione R, et al. Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17. Lancet. 2025. PMID: 40684778 Clinical Trial.
Clinical nutrition in the hepatogastroenterology curriculum.
Mulder CJ, Wanten GJ, Semrad CE, Jeppesen PB, Kruizenga HM, Wierdsma NJ, Grasman ME, van Bodegraven AA. Mulder CJ, et al. Among authors: van bodegraven aa. World J Gastroenterol. 2016 Feb 7;22(5):1729-35. doi: 10.3748/wjg.v22.i5.1729. World J Gastroenterol. 2016. PMID: 26855532 Free PMC article. Review.
Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.
Wijnands AM, Penning de Vries BBL, Lutgens MWMD, Bakhshi Z, Al Bakir I, Beaugerie L, Bernstein CN, Chang-Ho Choi R, Coelho-Prabhu N, Graham TA, Hart AL, Ten Hove JR, Itzkowitz SH, Kirchgesner J, Mooiweer E, Shaffer SR, Shah SC, Elias SG, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Wijnands AM, et al. Clin Gastroenterol Hepatol. 2024 Aug;22(8):1697-1708. doi: 10.1016/j.cgh.2024.02.014. Epub 2024 Feb 29. Clin Gastroenterol Hepatol. 2024. PMID: 38431223 Free article.
Lifestyle and psychosocial factors in inflammatory bowel disease: Prevalence, impact, motivation, and support needs.
Demers K, Hendrix EMB, Ardabili AR, Bredero QM, van Bodegraven AA, van der Horst D, Jonkers DMAE, Kimman ML, Mujagic Z, Romberg-Camps MJ, Römkens TEH, Scherpenzeel MP, Schroevers MJ, Stassen LPS, West RL, Dijkstra G, Pierik MJ. Demers K, et al. Among authors: van bodegraven aa. PLoS One. 2025 Aug 29;20(8):e0331092. doi: 10.1371/journal.pone.0331092. eCollection 2025. PLoS One. 2025. PMID: 40880377 Free PMC article.
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S. Danese S, et al. Among authors: van bodegraven aa. Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6. Dig Dis. 2019. PMID: 30726845 Free article.
294 results